[1] 候萌萌, 苑喜微, 王一奇, 等. 超声衰减参数在代谢相关脂肪性肝病诊断中的应用研究. 中华肝脏病杂志, 2022, 30(3): 290-296. [2] 徐春玲, 苗重昌, 刘雨成, 等. 应用MRI多回波水脂分离技术评估代谢相关性脂肪性肝病患者肝脏脂肪含量的临床意义. 实用肝脏病杂志, 2021, 24(2): 220-223. [3] Ahadi M, Molooghi K, Masoudifar N, et al. A review of non-alcoholic fatty liver disease in non-obese and lean individuals. J Gastroenterol Hepatol, 2021, 36(6): 1497-1507. [4] Ereqat S, Cauchi S, Eweidat K, et al. Association of DNA methylation and genetic variations of the APOE gene with the risk of diabetic dyslipidemia. Biomed Rep, 2022, 17(1): 61-70. [5] Wu X, Gong C, Weinstock J, et al. Associations of the SLCO1B1 polymorphisms with hepatic function, baseline lipid levels, and lipid-lowering response to simvastatin in patients with hyperlipidemia. Clin Appl Thromb Hemost, 2018, 24(9): 240-247. [6] Liu Q, Wu H, Yu Z, et al. APOE gene ε4 allele (388C-526C) effects on serum lipids and risk of coronary artery disease in southern Chinese Hakka population. J Clin Lab Anal, 2021, 35(9): e23925. [7] 中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会. 非酒精性脂肪性肝病防治指南(2018年更新版). 实用肝脏病杂志, 2018, 21(2): 177-186. [8] 吕璐, 平凡, 李玉秀. 他汀类药物治疗非酒精性脂肪性肝病获益及风险. 中华内分泌代谢杂志, 2021, 37(11): 1042-1048. [9] 吴滔, 邹耀威, 马剑达, 等. 类风湿关节炎患者非酒精性脂肪性肝病的特征及相关因素分析. 中华预防医学杂志, 2022, 56(5): 574-582. [10] Dabravolski SA, Bezsonov EE, Baig MS, et al. Mitochondrial mutations and genetic factors determining NAFLD risk. Int J Mol Sci, 2021, 22(9): 4459-4488. [11] Wu Y, Fang F, Wang Z, et al. The influence of recipient SLCO1B1 rs2291075 polymorphism on tacrolimus dose-corrected trough concentration in the early period after liver transplantation. Eur J Clin Pharmacol, 2021, 77(6): 859-867. [12] Song G, Chung JE, Yee J, et al. Effects of SLCO1B1 and SLCO1B3 genetic polymorphisms on valsartan pharmacokinetics in healthy Korean volunteers. J Pers Med, 2021, 11(9): 862-874. [13] Favela-Mendoza AF, Rodríguez-Rodríguez BG, Rojas-Prado E, et al. Prevalence of protective haplotypes of the SLCO1B1 gene for statin transport in Mexican populations. Per Med, 2021, 18(6): 533-540. [14] Mo Q, Huang S, Ma J, et al. Association between SLCO1B1 polymorphism distribution frequency and blood lipid level in Chinese adults. Br J Biomed Sci, 2021, 78(1): 23-27. [15] Park JW, Kim JM, Lee HY, et al. CYP3A5*3 and SLCO1B1 c. 521T>C polymorphisms influence the pharmacokinetics of atorvastatin and 2-hydroxy atorvastatin. Pharmaceutics, 2022, 14(7): 1491-1501. [16] Zhou T, Li H, Zhong H, et al. Association of apoE gene polymorphisms with lipid metabolism in renal diseases. Afr Health Sci, 2020, 20(3): 1368-1381. [17] 王娟, 杨柳, 权乾坤, 等. 老年人载脂蛋白E基因多态性和血脂代谢与心脑血管病的相关性研究. 中华老年医学杂志, 2020, 39(8): 883-886. [18] Nascimento JCR, Matos GA, Pereira LC, et al. Impact of apolipoprotein E genetic polymorphisms on liver disease: An essential review. Ann Hepatol, 2020, 19(1): 24-30. [19] Wu H, Huang Q, Yu Z, et al. The SNPs rs429358 and rs7412 of APOE gene are association with cerebral infarction but not SNPs rs2306283 and rs4149056 of SLCO1B1 gene in southern Chinese Hakka population. Lipids Health Dis, 2020, 19(1): 202-210. [20] 席宁, 王永辉, 周静, 等. ApoE基因多态性对缺血性脑梗死患者他汀类降脂药物治疗效果的影响. 中华医学遗传学杂志, 2022, 39(1): 94-98. |